Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators

被引:96
作者
McDonnell, DP [1 ]
Connor, CE [1 ]
Wijayaratne, A [1 ]
Chang, CY [1 ]
Norris, JD [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA
来源
RECENT PROGRESS IN HORMONE RESEARCH, VOL 57 | 2002年 / 57卷
关键词
D O I
10.1210/rp.57.1.295
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The term selective estrogen receptor modulators describes a group of pharmaceuticals that function as estrogen receptor (ER) agonists in some tissues but that oppose estrogen action in others. Although the name for this class of drugs has been adopted only recently, the concept is not new, as compounds exhibiting tissue-selective ER agonist/antagonist properties have been around for nearly 40 years. What is new is the idea that it may be possible to capitalize on the paradoxical activities of these drugs and develop them as target organ-selective ER agonists for the treatment of osteoporosis and other estrogenopathies. This realization has provided the impetus for research in this area, the progress of which is discussed in this review.
引用
收藏
页码:295 / 316
页数:22
相关论文
共 81 条
  • [1] ESTROGEN ACTION VIA THE CAMP SIGNALING PATHWAY - STIMULATION OF ADENYLATE-CYCLASE AND CAMP-REGULATED GENE-TRANSCRIPTION
    ARONICA, SM
    KRAUS, WL
    KATZENELLENBOGEN, BS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (18) : 8517 - 8521
  • [2] CLOMIPHENE PROTECTS AGAINST OSTEOPOROSIS IN THE MATURE OVARIECTOMIZED RAT
    BEALL, PT
    MISRA, LK
    YOUNG, RL
    SPJUT, HJ
    EVANS, HJ
    LEBLANC, A
    [J]. CALCIFIED TISSUE INTERNATIONAL, 1984, 36 (01) : 123 - 125
  • [3] TRANSCRIPTIONAL ACTIVATION BY THE ESTROGEN-RECEPTOR REQUIRES A CONFORMATIONAL CHANGE IN THE LIGAND-BINDING DOMAIN
    BEEKMAN, JM
    ALLAN, GF
    TSAI, SY
    TSAI, MJ
    OMALLEY, BW
    [J]. MOLECULAR ENDOCRINOLOGY, 1993, 7 (10) : 1266 - 1274
  • [4] TAMOXIFEN WITHDRAWAL RESPONSE - REPORT OF A CASE
    BELANI, CP
    PEARL, P
    WHITLEY, NO
    AISNER, J
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (02) : 449 - 450
  • [5] RALOXIFENE (LY139481 HCL) PREVENTS BONE LOSS AND REDUCES SERUM-CHOLESTEROL WITHOUT CAUSING UTERINE HYPERTROPHY IN OVARIECTOMIZED RATS
    BLACK, LJ
    SATO, M
    ROWLEY, ER
    MAGEE, DE
    BEKELE, A
    WILLIAMS, DC
    CULLINAN, GJ
    BENDELE, R
    KAUFFMAN, RF
    BENSCH, WR
    FROLIK, CA
    TERMINE, JD
    BRYANT, HU
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (01) : 63 - 69
  • [6] Molecular basis of agonism and antagonism in the oestrogen receptor
    Brzozowski, AM
    Pike, ACW
    Dauter, Z
    Hubbard, RE
    Bonn, T
    Engstrom, O
    Ohman, L
    Greene, GL
    Gustafsson, JA
    Carlquist, M
    [J]. NATURE, 1997, 389 (6652) : 753 - 758
  • [7] CANNEY PA, 1987, LANCET, V1, P36
  • [8] Clark J.H., 1988, P675
  • [9] CLARK JH, 1979, MONOGRAPHS ENDOCRINO, V14, P1
  • [10] Clarke M, 1998, LANCET, V351, P1451